Norwich Eaton's Didronel (etidronate)
Executive Summary
FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Didronel's use in treating postmenopausal osteoporosis on March 8. The meeting is currently scheduled to be held at FDA's Parklawn building in conference rooms D & E. The NDA was filed in July 1990. Didronel tablets are currently indicated for treating Paget's disease and heterotopic ossification following total hip replacement or spinal cord injury. Didronel I.V. is indicated for treating hypercalcemia of malignancy.